1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Sclnow Biotechnology Co. Ltd.
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Sumitomo Dainippon Pharma Co.
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Fujifilm Pharmaceuticals U.S.A., Inc.
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Johnson & Johnson Services, Inc.,
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. AstraZeneca,
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Celgene Corporation
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. F. Hoffmann-La Roche Ltd.,
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Onconova Therapeutics Inc.,
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. Amgen Inc.
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Apogenix AG,
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. GlaxoSmithKline plc.
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.12. SymBio Pharmaceuticals,
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.13. Kura Oncology, Inc.
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.14. Opsona Therapeutics,
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.15. CrystalGenomics Inc.,
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.16. Helsinn Healthcare SA.
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT
6.17. MEI Pharma Inc.,
6.17.1. Introduction
6.17.2. Financials
6.17.3. Products and Services
6.17.4. SWOT
6.18. Groupe Francophone des Myelodysplasies,
6.18.1. Introduction
6.18.2. Financials
6.18.3. Products and Services
6.18.4. SWOT
6.19. Acceleron Pharma, Inc.,
6.19.1. Introduction
6.19.2. Financials
6.19.3. Products and Services
6.19.4. SWOT
6.20. Boehringer Ingelheim International GmbH,
6.20.1. Introduction
6.20.2. Financials
6.20.3. Products and Services
6.20.4. SWOT
6.21. Karyopharm Therapeutics,
6.21.1. Introduction
6.21.2. Financials
6.21.3. Products and Services
6.21.4. SWOT
6.22. Eli Lilly and Company,
6.22.1. Introduction
6.22.2. Financials
6.22.3. Products and Services
6.22.4. SWOT
6.23. AbbVie Inc.,
6.23.1. Introduction
6.23.2. Financials
6.23.3. Products and Services
6.23.4. SWOT
6.24. Amphivena Therapeutics Inc.,
6.24.1. Introduction
6.24.2. Financials
6.24.3. Products and Services
6.24.4. SWOT
6.25. MabVax Therapeutics Holdings, Inc.,
6.25.1. Introduction
6.25.2. Financials
6.25.3. Products and Services
6.25.4. SWOT
6.26. medac GmbH,
6.26.1. Introduction
6.26.2. Financials
6.26.3. Products and Services
6.26.4. SWOT
6.27. Astex Pharmaceuticals,
6.27.1. Introduction
6.27.2. Financials
6.27.3. Products and Services
6.27.4. SWOT
6.28. Stemline Therapeutics Inc.,
6.28.1. Introduction
6.28.2. Financials
6.28.3. Products and Services
6.28.4. SWOT
6.29. Calithera Biosciences Inc.,
6.29.1. Introduction
6.29.2. Financials
6.29.3. Products and Services
6.29.4. SWOT
6.30. Array BioPharma,
6.30.1. Introduction
6.30.2. Financials
6.30.3. Products and Services
6.30.4. SWOT
6.31. Mirati Therapeutics,
6.31.1. Introduction
6.31.2. Financials
6.31.3. Products and Services
6.31.4. SWOT
6.32. Qol-one,
6.32.1. Introduction
6.32.2. Financials
6.32.3. Products and Services
6.32.4. SWOT
6.33. Syros Pharmaceuticals Inc.,
6.33.1. Introduction
6.33.2. Financials
6.33.3. Products and Services
6.33.4. SWOT
6.34. Kyowa Kirin Pharmaceutical Development Inc.,
6.34.1. Introduction
6.34.2. Financials
6.34.3. Products and Services
6.34.4. SWOT
6.35. Aileron Therapeutics, Medpacto Inc.,
6.35.1. Introduction
6.35.2. Financials
6.35.3. Products and Services
6.35.4. SWOT
6.36. Pfizer Inc.,
6.36.1. Introduction
6.36.2. Financials
6.36.3. Products and Services
6.36.4. SWOT
6.37. BioMed Valley Discoveries Inc.,
6.37.1. Introduction
6.37.2. Financials
6.37.3. Products and Services
6.37.4. SWOT
6.38. BioLineRx.,
6.38.1. Introduction
6.38.2. Financials
6.38.3. Products and Services
6.38.4. SWOT
6.39. CTI BioPharma Corp.,
6.39.1. Introduction
6.39.2. Financials
6.39.3. Products and Services
6.39.4. SWOT
6.40. Sunesis Pharmaceuticals Inc.,
6.40.1. Introduction
6.40.2. Financials
6.40.3. Products and Services
6.40.4. SWOT
6.41. Immune System Key (Isk) Ltd.,
6.41.1. Introduction
6.41.2. Financials
6.41.3. Products and Services
6.41.4. SWOT
6.42. Takeda Pharmaceutical Company Limited.,
6.42.1. Introduction
6.42.2. Financials
6.42.3. Products and Services
6.42.4. SWOT
6.43. BerGenBio ASA,
6.43.1. Introduction
6.43.2. Financials
6.43.3. Products and Services
6.43.4. SWOT
6.44. Cell Medica,
6.44.1. Introduction
6.44.2. Financials
6.44.3. Products and Services
6.44.4. SWOT
6.45. FortySeven Inc.,
6.45.1. Introduction
6.45.2. Financials
6.45.3. Products and Services
6.45.4. SWOT
6.46. Imago BioSciences,
6.46.1. Introduction
6.46.2. Financials
6.46.3. Products and Services
6.46.4. SWOT
6.47. CytoDyn Inc.,
6.47.1. Introduction
6.47.2. Financials
6.47.3. Products and Services
6.47.4. SWOT
6.48. OncoTherapy Science Inc.,
6.48.1. Introduction
6.48.2. Financials
6.48.3. Products and Services
6.48.4. SWOT
6.49. Mateon Therapeutics Inc.,
6.49.1. Introduction
6.49.2. Financials
6.49.3. Products and Services
6.49.4. SWOT
6.50. Bellicum Pharmaceuticals, Inc.
6.50.1. Introduction
6.50.2. Financials
6.50.3. Products and Services
6.50.4. SWOT
6.51. Daiichi Sankyo Company, Limited.,
6.51.1. Introduction
6.51.2. Financials
6.51.3. Products and Services
6.51.4. SWOT
6.52. Plexxikon, FibroGen, Inc.,
6.52.1. Introduction
6.52.2. Financials
6.52.3. Products and Services
6.52.4. SWOT
6.53. argenx US Inc.,
6.53.1. Introduction
6.53.2. Financials
6.53.3. Products and Services
6.53.4. SWOT
6.54. Kiadis Pharma,
6.54.1. Introduction
6.54.2. Financials
6.54.3. Products and Services
6.54.4. SWOT
6.55. Aprea Therapeutics,
6.55.1. Introduction
6.55.2. Financials
6.55.3. Products and Services
6.55.4. SWOT
6.56. Forma Therapeutics, Inc.,
6.56.1. Introduction
6.56.2. Financials
6.56.3. Products and Services
6.56.4. SWOT
6.57. Agios, Inc.
6.57.1. Introduction
6.57.2. Financials
6.57.3. Products and Services
6.57.4. SWOT
6.58. Actinium Pharmaceuticals Inc.,
6.58.1. Introduction
6.58.2. Financials
6.58.3. Products and Services
6.58.4. SWOT
6.59. Aeglea BioTherapeutics,
6.59.1. Introduction
6.59.2. Financials
6.59.3. Products and Services
6.59.4. SWOT
6.60. BAYER AG,
6.60.1. Introduction
6.60.2. Financials
6.60.3. Products and Services
6.60.4. SWOT
6.61. Altor BioScience,
6.61.1. Introduction
6.61.2. Financials
6.61.3. Products and Services
6.61.4. SWOT
6.62. Rafael Pharmaceuticals, Inc.,
6.62.1. Introduction
6.62.2. Financials
6.62.3. Products and Services
6.62.4. SWOT
6.63. H3 Biomedicine Inc.,
6.63.1. Introduction
6.63.2. Financials
6.63.3. Products and Services
6.63.4. SWOT
6.64. Cellerant Therapeutics, Inc.,
6.64.1. Introduction
6.64.2. Financials
6.64.3. Products and Services
6.64.4. SWOT
6.65. Boston Biomedical.
6.65.1. Introduction
6.65.2. Financials
6.65.3. Products and Services
6.65.4. SWOT
6.66. Gamida Cell
6.66.1. Introduction
6.66.2. Financials
6.66.3. Products and Services
6.66.4. SWOT
List of Tables
List of Figures